First, using mutant derivatives, we showed that the presence of two or three consecutive T-residues in the ribozyme portion was sufficient to promote the release of anomalous short transcripts. Second, when the ribozyme did not contain T-rich sequence, full-length transcripts were produced, but these transcripts were very unstable and were retained in the cell nucleus. In contrast, insertion of the ribozyme in place of the central do-
. Indeed, pol Ill-transcribed genes are easy to manipulate, as these genes are usually small and contain internal or external well-defined promoter regions (Galli et al., 1981; Geiduschek, 1988; Goodrich and Tjian, 1994) . In addition, the 3'-end of the gene is characterized by the presence of a run of four to six consecutive T-residues that act as a strong transcription termination signal INTRODUCTION The possibility of modulating gene expression via the intracellular delivery of small therapeutic RNAs has emerged recently as a promising approach for the future treatment of various diseases. Several RNA-based molecular tools have been developed, including RNA decoys, antisense RNAs, and ribozymes. Particularly, the intracellular expression of modified RNAs designed to inhibit human immunodeficiency virus (HIV) replication is one direction for AIDS gene therapy (Yu et al., 1994; Bertrand and Rossi, 1996) . One potential advantage over conventional drug delivery is the ability of expressing these therapeutic RNAs continually in pathogenic cells after stable gene transfer. In addition, RNA-based approaches may be of particular interest because it is unlikely that cells expressing therapeutic RNAs serve as targets for the host immune RNA molecule that is accumulated to high levels in the cell cytoplasm of adenovirus-infected cells (Mellits et al., 1990; Ghadge et al., 1994; Rahman et al., 1995; Ma and Matthews, 1996) . This small RNA interacts with an interferon (IFN) induced protein kinase (PKR) to prevent its activation, which would otherwise shut down translation through the phosphorylation of eukaryotic initiation factor 2 (eIF-2) (Thimmappaya et al., 1982; Akusjarvi et al., 1987; Matthews and Shenk, 1991) .
In a previous study (Cagnon et al., 1995) (Haseloff and Gerlach, 1988; Marschall et al., 1994; Symons, 1994) . However, the intracellular activity of ribozymes is highly variable, and the parameters controlling their efficiency in vivo are not clearly defined. It has been shown that the association step between the ribozyme and its target is the determining step inside the cells (Sullenger and Cech, 1993; Bertrand and Rossi, 1996; Bertrand et al., 1997) .
Thus, intracellular ribozyme concentration has to be as high as possible, and the ribozyme should reach the same subcellular localization as its target RNA (Bertrand et al., 1997; Hormes et al., 1997) . In addition, intracellular folding of the ribozyme is critical for its activity. It is thus important to carefully optimize the design of the RNA molecule used to carry the ribozyme into cells, as this will affect all these parameters (Thompson et al., 1995; Prislei et al., 1997) .
In the present study, we show that intracellular expression of chimeric VAI RNAs that contain hammerhead ribozymes appended at their 3'-end reveal several anomalies in RNA termination, stability, and localization. The nature and the position of the ribozyme may profoundly affect expression of the VAI RNA in mammalian cells. We conclude that regulation of a pol Ill-transcribed gene is a complex process involving more than the intragenic promoter. These results will be useful for the future design of intracellular active ribozyme. (Boerhinger Mannheim) . RNA extraction and analysis were performed as previously described (Cagnon et al., 1995) . For Northern blot analysis, membranes were probed with radiolabeled oligonucleotides complementary either to the 5'-end of the VAI RNA, VAS2, GCCATGATACCCTTGCGAATT-TATCCACCAGACCA, or to the central domain of VASIV RNA, VASM, CACGGCGGACGGCCGGATCCGGGG. As indicated, the pCMV /3-gal control plasmid furnished with the transfection kit (a plasmid harboring the jS-galactosidase gene under the CMV promoter) was cotransfected (0.5 pg) with plasmids encoding for the different ribozymes (5 pg). Northern blots were subsequently probed with a VAI or a )3-gal-specific probe. The level of expression of the ß-gal mRNA was used as an internal control to normalize transfection efficiency. The half-life (tll2) determination of VAI-modified RNAs was determined as previously described (Cagnon et al., 1995) .
MATERIALS AND METHODS

Construction ofmodified VAI
In situ hybridizations
In situ hybridizations were performed as previously described (Bertrand et al., 1997) (Fig. 1) . Thus, the VAI RNA was devoid of its ability to block the activation of PKR, as the integrity of the VAI RNA central domain is required to retain this function (Mellits et al., 1990; Rahman et al., 1995) . As shown, the VASIV RNA is shorter than the parental Ad2 VAI RNA (134 nt instead of 160 nt) and consists essentially of an extended double-strand axis containing few mismatches (Fig.   1A ). In addition, a new internal restriction site (Eco RV) was created to facilitate subsequent addition of exogenous sequences inside the VAI central domain.
To inhibit replication of HIV-1, eight chimeric VASIV RNAs were constructed that contained hammerhead ribozymes designed to cleave conserved regions of the HIV-1BRU Gag encoding mRNA. Each anti-HIV hammerhead ribozyme may be divided into six functional domains (Fig. IB) . The consensus sequence for the catalytic core was initially described by Haseloff and Gerlach (1988) , and the variable flanking sequences involved in the specific recognition of the target HIV RNA, which were termed specifier I and II, contained either 7 or 8 nucleotides. These ribozymes were introduced into the Eco47 III cloning site of VASIV, very near its 3' end ( Fig. IB) . Thus, it was expected that the ribozymes could fold properly into active conformation, as they appeared to be relatively free of intramolecular hybridization with the nonribozyme sequence (not shown).
Ribozyme catalytic activity for each anti-HIV VASIV RBZ was tested by analyzing in vitro the efficiency of convertion of HIV RNA substrates into the corresponding cleavage products ( Fig. 2A,B (Fig. 4C, VAS2 ), VASIV RBZ 10 transcript was not detected when the same Northern blot was probed with a ribozyme-specific probe (Fig.  4C, RBZlOp) . Thus, the lack of ribozyme moiety was sufficient to explain that the VASIV RBZ 10 was shorter than expected. These observations and further investigations led us to conclude that highly expressed chimeric VASIV RBZ genes were all shorter than their expected size, whereas the VASIV RBZs that gave rise to full-length transcripts were weakly expressed.
Identification of sequence elements responsible for the short length of the chimeric VAbTV RBZs Because the eight anti-HIV ribozyme constructs differ from each other only by the variable specifier sequences, it was hypothesized that these sequences might contain signals responsible for the aberrant expression of these pol Ill-transcribed genes. A sequence comparison has revealed that most of the chimeric genes that gave rise to anomalous short transcripts (i.e., RBZ4, 10, 19 , and 36) contained several T-residues in the specifier I (see Fig. 1, underlined sequences) . Therefore, we hypothesized that the presence of a run of T-residues could be responsible for the release of incomplete transcripts. This hypothesis was tested by generating three VASIV RBZ10 mutated genes that contained a modified run of T-residues (Fig. 4A) . For RBZ 10* the run of three T-residues was interrupted by replacing the second T by A, RBZ 10** was devoid of T-residues, and for RBZ10S, the G-residue that follows the run of T was replaced by a T-residue to introduce a wild-type pol III transcription termination signal (four consecutive T-residues).
The intracellular expression of these different VASIV RBZ 10 mutated genes was analyzed in transiently transfected 293 cells through Northern blot analysis (Fig. 4B,C) (Fig. 4C, RBZlOp) . Third, results obtained with RBZ10" constructs ( Fig. 4B) extended these observations by showing that in the absence of T-residue in specifier I, only a larger full-length transcript was detected. These results argued that the run of three T-residues, located at the beginning of the RBZ 10 sequence, played a critical role in the intracellular production of anomalously incomplete transcripts lacking the ribozyme sequence.
This result, however, seemed to contradict observations we made in a previous study (Cagnon et al., 1995) . In this work, a short antisense sequence (crev sequence) was added inside the central domain of the VAI RNA to give rise to chimeric antisense RNA, termed VAcrev. It was shown that despite the fact that this sequence contained a run of three T-residues, the appearance of shortened transcripts was never observed. To explain this discrepancy, we generated new constructs that contained ribozyme 10 derived-sequences substituted for the VAI RNA central domain (Fig. 5A ) (RBZlOint and RBZlOSint). Thus, a new family of chimeric VAI RBZ genes, refered as VASIV RBZint genes, was generated. 293 cells were transiently transfected with these constructs, and RNA expression was analyzed using Northern blot (Fig. 5B) (Fig. 6 ). After transfection, the cells were treated (or not) with actinomycin D to block all endogeneous transcriptional activities. RNAs were extracted at different times and analyzed by Northern blot to quantify the expression level of the VASIV RBZ 10*. The stability of the two RNA species was very different. As shown in Figure 6 , the fulllength transcript was very unstable (tm < 1.5 hours) compared with the short one (r//2 = 7.5 hours). Concurrently, the tI/2 measured for the VASIV RBZ 10 transcript was comparable to those of the short VASIV BZ10* transcript (tm around 7 hours) (Fig.  6B ) and of the parental VASIV RNA carrier (tlj2 around 6.5 hours) (data not shown).
Subcellular localization of RNAs expressed from various cassettes derived from the VAI gene In addition to its abundance, the ribozyme ideally should be cytoplasmic in order to target mRNA (Bertrand et al., 1997;  In situ localization of the various ribozymes derived from VASIV cassette expression. Transiently transfected COS cells expressing the different constructs developed for this study were hybridized in situ with an RNA probe specific for VAI RNA. Probe detection was performed using the alkaline phosphatase color reaction as described in Materials and Methods. Cells were transfected with wild-type VAI RNA (A) and VASIV RNA (B) expression plasmids, and the following ribozymes expression cassette: VASIV RBZlOint (C), VASIV RBZlOSint (D), VASIV RBZlO'int (E), VASIV RBZ10 (F), VASIV RBZ10S (G), VASIV RBZ10* (H), and VASIV RBZ10" (I). Hormes et al., 1997) . The VAI RNA is cytoplasmic, but it was not known if the various modifications we introduced would modify its localization. Because 293 cells are relatively small cells, it was difficult to obtain a good spatial resolution for compartmentalization studies. To overcome these difficulties, COS cells were used, although similar results were obtained using 293 cells. COS cells were transiently transfected with the various cassettes derived from the VAI RNA gene, including mutants of the RBZ 10, and processed for in situ hybridizations (Fig. 7) . As expected from a previous study, wild-type Ad2 VAI RNA accumulated in the cytoplasm (Fig. 7A) . By deleting the VAI RNA central domain, this localization was not modified, as the VASIV RNA was also found in cytoplasm (Fig.  7B) . Similarly, chimeric genes in which the ribozyme was appended at the 3'-end of the VASIV and which produced an anomalous short transcript that is almost identical to the VASIV RNA (VASIV RBZ10 and VASIV RBZ10S) produced a cytoplasmic transcript (Fig. 7F,G) . More interestingly, constructs in which the added sequence RNA was inserted instead of the central domain (VASIV RBZlOint and VAcrev) were also cytoplasmic (Fig. 7C,E) . This shows that the central domain was not required for cytoplasmic export of the VAI RNA and that many sequences can be introduced at this site without inhibiting export.
Finally, the VASIV RBZlOSint (Fig. 7D) (Fig. 7H) , which generated two different RNA molecular species in cells and for which transcripts are detected both in the nucleus and in the cytoplasm.
DISCUSSION
The regulation of pol Ill-dependent gene expression is usually believed to involve simple regulator elements. Their promoters can be internal or external to the transcription unit but usually contain a small number of short functional consensus motifs (Geiduschek, 1988; Campbell and Setzer, 1992 (Maraia et al., 1994) (Thompson et al., 1995; Prislei et al., 1997) . It is likely that when the RBZ is added inside the VASIV RNA molecule, it does not fold into a proper conformation that favors its catalytic activity. However, the structure of these chimeras can be further optimized to allow for higher ribozyme activity (Thompson et al., 1995) 
